Patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation had greater improvements in quality of ...

Effective treatment with dupilumab may allow younger children with severe atopic dermatitis and short stature to catch up on ...

In a major potential step toward personalized therapy for atopic dermatitis, data suggest early, late, and no clinical ...

Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and ...

The following is a summary of “Clinical Effectiveness and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease ...

27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab ...

A new study published in the Journal of American Academy of Dermatology found that Dupilumab improved atopic dermatitis (AD) ...

New trial results show dupilumab significantly improves remission rates and reduces symptoms in patients with bullous ...

The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...

Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and ...

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven in part by type 2 inflammation or other allergic processes in ...